Photocatalytic three-component radical cascade: a general route

to heterocyclic-substituted alkyl sulfones

Jian-Qiang Chen,^a Nana Liu, ^a Qian Hu,^a Jin Liu,^a Junwei Wu,^a Qinling Cai^a and Jie Wu^{*a,b,c} ^a Institute for Advanced Studies, Taizhou University, 1139 Shifu Avenue, Taizhou 318000, China ^b State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China ^c School of Chemistry and Chemical Engineering, Henan Normal University, 46 East Jianshe Road, Xinxiang 453007, China

Supporting Information

- 1. General experimental method (S2)
- 2. General experimental procedure (S3-S4)
- 3. Radical trapping experiment (S5-S6)
- 4. Devices for the photocatalytic reactions (S7)
- 5. Characterization data of compounds (S8-S21)
- 6. ¹H NMR and ¹³C NMR spectra of compounds (S22-S87)

General experimental methods:

Unless otherwise stated, all commercial reagents were used as received. All solvents were dried and distilled according to standard procedures. Flash column chromatography was performed using silica gel (60-Å pore size, 32-63µm, standard grade). Analytical thin-layer chromatography was performed using glass plates pre-coated with 0.25 mm 230-400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were visualized by exposure to ultraviolet light. Organic solutions were concentrated on rotary evaporators at ~20 Torr at 25-35 °C. Nuclear magnetic resonance (NMR) spectra are recorded in parts per million from internal tetramethylsilane on the δ (ppm) scale. ¹H NMR ¹⁹F NRM and ¹³C NMR spectra were recorded in CDCl₃ on a Bruker DRX - 400 spectrometer operating at 400 MHz ³⁷⁶ MHz and 100 MHz respectively. All chemical shift values are quoted in ppm and coupling constants quoted in Hz. High resolution mass spectrometry (HRMS) spectra were obtained on a micrOTOF II Instrument.

General experimental procedure for the visible-light-induced sulfonylation of oxime **1**, DABSO and alkene **2**.



A dry tube was charged with oxime **1** (0.3 mmol), DABSO (0.2 mmol), alkene **2** (0.2 mmol) and Mes-Acr·ClO₄ (4.0 mol %), sealed with a rubber stopper, evacuated and backfilled with argon for four times before the addition of DCE (3.0 mL) *via* a syringe. The mixture was then placed around a blue LED (24 W) with a distance of 10 centimeters, and was stirred under blue light irradiation for 24 hours at room temperature. After completion of reaction as indicated by TLC, the solvent was evaporated in vacuo, and purified by flash column chromatography (EtOAc/*n*-hexane, 1:3) to provide the desired product **3**.

General experimental procedure for the aminosulfonylation of $\beta_{,\gamma}$ -unsaturated hydrazones **4** with DABSO and alkene **2**.



A dry tube was charged with β , γ -unsaturated hydrazones **4** (0.2 mmol), DABSO (0.2 mmol), alkene **2** (0.3 mmol) and 4CzIPN (2.0 mol %), sealed with a rubber stopper, evacuated and backfilled with argon for four times before the addition of DMF (3.0 mL) *via* a syringe. The mixture was then placed around a blue LED (24 W) with a distance of 10 centimeters, and was stirred under blue light irradiation for 24 hours at room temperature. After completion of reaction as indicated by TLC, the solvent was evaporated in *vacuo*, and purified by flash column chromatography (EtOAc/*n*-hexane, 1:2) to provide the desired product **5**.

Radical trapping experiment



A dry tube was charged with (*E*)-1-(*p*-tolyl)but-3-en-1-one oxime **1a** (0.3 mmol), DABSO (0.2 mmol), 2-vinylpyridine **2a** (0.2 mmol), Mes-Acr⁺ (4.0 mol %) and TEMPO (0.4 mmol), sealed with a rubber stopper, evacuated and backfilled with argon for four times before the addition of DCE (3.0 mL) *via* a syringe. The mixture was then placed around a blue LED (24 W) with a distance of 10 centimeters, and was stirred under blue light irradiation for 24 hours at room temperature. After completion of reaction as indicated by TLC, only a trace of the desired product **3a** was detected.



А dry tube charged with was (E)-4-methyl-N'-(1-phenylbut-3-en-1-ylidene)benzenesulfonohydrazide 4a (0.2 mmol), DABSO (0.2 mmol), 2-vinylpyridine 2a (0.3 mmol), 4CzIPN (2.0 mol %) and TEMPO (0.4 mmol), sealed with a rubber stopper, evacuated and backfilled with argon for four times before the addition of DMF (3.0 mL) via a syringe. The mixture was then placed around a blue LED (24 W) with a distance of 10 centimeters, and was stirred under blue light irradiation for 24 hours at room temperature. After completion of reaction as indicated by TLC, only a trace of the desired product 5a was detected.

Devices for the photocatalytic reactions





5-(((2-(Pyridin-2-yl)ethyl)sulfonyl)methyl)-3-(*p*-tolyl)-4,5-dihydroisoxazole (**3a**) ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.53 (d, *J* = 4.3 Hz, 1H), 7.63 (td, *J* = 7.7, 1.8 Hz, 1H), 7.54 (d, *J* = 8.2 Hz, 2H), 7.25 (d, *J* = 7.9 Hz, 1H), 7.22 (d, *J* = 8.0 Hz, 2H), 7.17 (dd, *J* = 7.2, 5.1 Hz, 1H), 5.25 (dq, *J* = 10.5, 6.8 Hz, 1H), 3.70 (td, *J* = 7.1, 2.0 Hz, 2H), 3.62 (dd, *J* = 17.0, 10.4 Hz, 1H), 3.49 (dd, *J* = 14.4, 6.9 Hz, 1H), 3.38 – 3.27 (m, 3H), 3.14 (dd, *J* = 14.4, 5.7 Hz, 1H), 2.38 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 157.0, 156.9, 149.5, 141.0, 136.8, 129.5, 126.7, 125.7, 123.3, 122.0, 74.6, 57.3, 53.6, 40.5, 29.9, 21.4; HRMS calcd for C₁₈H₂₀N₂NaO₃S⁺ (M+Na⁺): 367.1087, found: 367.1095.



3-(4-(*tert*-Butyl)phenyl)-5-(((2-(pyridin-2-yl)ethyl)sulfonyl)methyl)-4,5-dihydroisoxazo le (**3b**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.53 (d, *J* = 4.2 Hz, 1H), 7.66 – 7.58 (m, 3H), 7.44 (d, *J* = 8.4 Hz, 2H), 7.25 (d, *J* = 7.8 Hz, 1H), 7.19 – 7.15 (m, 1H), 5.30 – 5.21 (m, 1H), 3.72 – 3.59 (m, 3H), 3.49 (dd, *J* = 14.4, 6.9 Hz, 1H), 3.39 – 3.29 (m, 3H), 3.14 (dd, *J* = 14.4, 5.7 Hz, 1H), 1.33 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 157.0, 156.8, 154.1, 149.5, 136.8, 126.6, 125.8, 125.7, 123.3, 122.0, 74.6, 57.3, 53.6, 40.5, 34.9, 31.1, 29.9; HRMS calcd for C₂₁H₂₆N₂NaO₃S⁺ (M+Na⁺): 409.1556, found: 409.1563.



3-(4-Methoxyphenyl)-5-(((2-(pyridin-2-yl)ethyl)sulfonyl)methyl)-4,5-dihydroisoxazole (**3c**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.53 (d, J = 4.4 Hz, 1H), 7.66 – 7.61 (m, 1H), 7.59 (d, J = 8.8 Hz, 2H), 7.25 (d, J = 7.8 Hz, 1H), 7.16 (dd, J = 7.2, 5.1 Hz, 1H), 6.92 (d, J = 8.8 Hz,

2H), 5.23 (dq, J = 10.5, 6.7 Hz, 1H), 3.84 (s, 3H), 3.72 – 3.67 (m, 2H), 3.60 (dd, J = 16.9, 10.4 Hz, 1H), 3.49 (dd, J = 14.4, 6.9 Hz, 1H), 3.37 – 3.26 (m, 3H), 3.14 (dd, J = 14.4, 5.7 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 161.4, 157.0, 156.5, 149.5, 136.7, 128.4, 123.3, 122.0, 121.0, 114.2, 74.5, 57.2, 55.3, 53.6, 40.6, 29.9; HRMS calcd for C₁₈H₂₀N₂NaO₄S⁺ (M+Na⁺): 383.1036, found: 383.1041.



3-Phenyl-5-(((2-(pyridin-2-yl)ethyl)sulfonyl)methyl)-4,5-dihydroisoxazole (**3d**) ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.53 (d, *J* = 4.3 Hz, 1H), 7.68 – 7.61 (m, 3H), 7.42 (q, *J* = 5.2 Hz, 3H), 7.25 (d, *J* = 8.5 Hz, 1H), 7.17 (dd, *J* = 6.9, 5.3 Hz, 1H), 5.28 (dq, *J* = 12.9, 6.6 Hz, 1H), 3.75 – 3.61 (m, 3H), 3.50 (dd, *J* = 14.4, 6.8 Hz, 1H), 3.40 – 3.30 (m, 3H), 3.16 (dd, *J* = 14.4, 5.8 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 156.9, 149.5, 136.8, 130.6, 128.8, 128.6, 126.8, 123.4, 122.1, 74.8, 57.3, 53.6, 40.4, 29.9; HRMS calcd for C₁₇H₁₈N₂NaO₃S⁺ (M+Na⁺): 353.0930, found: 353.0935.



3-(4-Chlorophenyl)-5-(((2-(pyridin-2-yl)ethyl)sulfonyl)methyl)-4,5-dihydroisoxazole (**3e**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.54 (d, *J* = 4.3 Hz, 1H), 7.64 (td, *J* = 7.7, 1.8 Hz, 1H), 7.59 (d, *J* = 8.6 Hz, 2H), 7.39 (d, *J* = 8.6 Hz, 2H), 7.25 (d, *J* = 7.9 Hz, 1H), 7.18 (dd, *J* = 7.0, 5.2 Hz, 1H), 5.28 (dq, *J* = 10.6, 6.6 Hz, 1H), 3.70 (td, *J* = 7.3, 3.4 Hz, 2H), 3.61 (dd, *J* = 17.0, 10.5 Hz, 1H), 3.49 (dd, *J* = 14.4, 6.5 Hz, 1H), 3.39 – 3.30 (m, 3H), 3.16 (dd, *J* = 14.4, 6.2 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 156.9, 156.1, 149.5, 136.8, 136.6, 129.1, 128.0, 127.1, 123.4, 122.1, 75.0, 57.1, 53.6, 40.2, 29.9; HRMS calcd for C₁₇H₁₇ClN₂NaO₃S⁺ (M+Na⁺): 387.0541, found: 387.0548.



3-(3-Chlorophenyl)-5-(((2-(pyridin-2-yl)ethyl)sulfonyl)methyl)-4,5-dihydroisoxazole (**3f**) ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.54 (d, *J* = 4.1 Hz, 1H), 7.64 (ddd, *J* = 9.5, 5.6, 1.8 Hz, 2H), 7.55 – 7.52 (m, 1H), 7.43 – 7.33 (m, 2H), 7.25 (d, *J* = 7.8 Hz, 1H), 7.17 (dd, *J* = 7.0, 5.2 Hz, 1H), 5.29 (dq, *J* = 10.6, 6.6 Hz, 1H), 3.73 – 3.58 (m, 3H), 3.49 (dd, *J* = 14.4, 6.6 Hz, 1H), 3.38 – 3.30 (m, 3H), 3.17 (dd, *J* = 14.4, 6.1 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 156.9, 156.0, 149.5, 136.8, 134.9, 130.5, 130.3, 130.1, 126.8, 124.9,

123.3, 122.1, 75.1, 57.1, 53.6, 40.1, 29.9; HRMS calcd for C₁₇H₁₇ClN₂NaO₃S⁺ (M+Na⁺): 387.0541, found: 387.0551.



3-(2-Chlorophenyl)-5-(((2-(pyridin-2-yl)ethyl)sulfonyl)methyl)-4,5-dihydroisoxazole (3g)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.54 (s, 1H), 7.68 – 7.62 (m, 2H), 7.53 (d, *J* = 7.6 Hz, 1H), 7.38 (dt, *J* = 15.6, 4.8 Hz, 2H), 7.19 (s, 2H), 5.33 – 5.25 (m, 1H), 3.74 – 3.57 (m, 3H), 3.50 (dd, *J* = 14.4, 6.6 Hz, 1H), 3.39 – 3.29 (m, 3H), 3.18 (dd, *J* = 14.4, 6.0 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 156.8, 156.0, 149.4, 136.9, 134.8, 130.5, 130.3, 130.1, 126.8, 124.9, 123.4, 122.1, 75.1, 57.1, 53.6, 40.1, 29.9; HRMS calcd for C₁₇H₁₇ClN₂NaO₃S⁺ (M+Na⁺): 387.0541, found: 387.0548.



4-(5-(((2-(Pyridin-2-yl)ethyl)sulfonyl)methyl)-4,5-dihydroisoxazol-3-yl)benzonitrile (**3h**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.54 (d, J = 4.3 Hz, 1H), 7.77 (d, J = 8.5 Hz, 2H),

7.71 (d, J = 8.5 Hz, 2H), 7.65 (td, J = 7.7, 1.7 Hz, 1H), 7.25 (d, J = 7.8 Hz, 1H), 7.19 (dd, J = 6.9, 5.3 Hz, 1H), 5.38 – 5.30 (m, 1H), 3.74 – 3.61 (m, 3H), 3.51 (dd, J = 14.3, 6.2 Hz, 1H), 3.42 – 3.34 (m, 3H), 3.20 (dd, J = 14.3, 6.5 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 156.7, 155.8, 149.5, 136.8, 132.9, 132.6, 127.3, 123.4, 122.2, 118.1, 113.9, 75.6, 56.9, 53.6, 39.7, 29.9; HRMS calcd for C₁₈H₁₇N₃NaO₃S ⁺ (M+Na⁺): 378.0883, found: 378.0890.



5-(((2-(Pyridin-2-yl)ethyl)sulfonyl)methyl)-3-(thiophen-2-yl)-4,5-dihydroisoxazole (**3i**) ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.53 (d, *J* = 4.2 Hz, 1H), 7.64 (td, *J* = 7.7, 1.6 Hz, 1H), 7.43 (d, *J* = 4.5 Hz, 1H), 7.24 (t, *J* = 5.5 Hz, 2H), 7.17 (dd, *J* = 7.1, 5.2 Hz, 1H), 7.08 (dd, *J* = 4.9, 3.8 Hz, 1H), 5.30 – 5.22 (m, 1H), 3.72 – 3.61 (m, 3H), 3.50 (dd, *J* = 14.4, 6.9 Hz, 1H), 3.37 – 3.31 (m, 3H), 3.16 (dd, *J* = 14.4, 5.7 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 156.9, 152.7, 149.4, 136.8, 130.8, 129.2, 128.9, 127.5, 123.3, 122.1, 75.0, 57.0, 53.6, 41.1, 29.8; HRMS calcd for C₁₅H₁₆N₂NaO₃S₂⁺ (M+Na⁺): 359.0495, found: 359.0495.



5-(((2-(Pyridin-4-yl)ethyl)sulfonyl)methyl)-3-(*p*-tolyl)-4,5-dihydroisoxazole (**3j**) ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.56 (dd, *J* = 4.4, 1.4 Hz, 2H), 7.55 (d, *J* = 8.1 Hz, 2H), 7.23 (d, *J* = 7.2 Hz, 4H), 5.31 – 5.23 (m, 1H), 3.65 (dd, *J* = 16.9, 10.5 Hz, 1H), 3.55 – 3.42 (m, 3H), 3.27 – 3.12 (m, 4H), 2.39 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 157.0, 150.2, 146.5, 141.3, 129.6, 126.8, 125.4, 123.8, 74.8, 57.6, 54.7, 40.6, 27.3, 21.5; HRMS calcd for C₁₈H₂₀N₂NaO₃S⁺ (M+Na⁺): 367.1087, found: 367.1095.



3-(*p*-Tolyl)-5-(((2-(5-(trifluoromethyl)pyridin-2-yl)ethyl)sulfonyl)methyl)-4,5-dihydrois oxazole (**3k**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.80 (s, 1H), 7.88 (dd, *J* = 8.1, 1.8 Hz, 1H), 7.55 (d, *J* = 8.1 Hz, 2H), 7.40 (d, *J* = 8.1 Hz, 1H), 7.23 (d, *J* = 8.0 Hz, 2H), 5.31 – 5.23 (m, 1H), 3.77 – 3.72 (m, 2H), 3.64 (dd, *J* = 16.9, 10.5 Hz, 1H), 3.54 (dd, *J* = 14.6, 7.6 Hz, 1H), 3.46 – 3.42 (m, 2H), 3.29 (dd, *J* = 16.9, 6.8 Hz, 1H), 3.19 (dd, *J* = 14.6, 4.7 Hz, 1H), 2.39 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 161.1, 156.9, 146.4 (q, *J* = 4.0 Hz), 141.1, 133.8 (q, *J* = 3.3 Hz), 129.6, 126.8, 125.6, 123.5 (q, *J* = 272.4 Hz), 123.1, 74.7, 57.6, 53.1, 40.6, 29.8, 21.5; HRMS calcd for C₁₉H₁₉F₃N₂NaO₃S ⁺ (M+Na⁺): 435.0961, found: 435.0970.



1-Phenyl-3-(((3-(*p*-tolyl)-4,5-dihydroisoxazol-5-yl)methyl)sulfonyl)propan-1-one (**3**I) ¹H NMR (400 MHz, DMSO) δ (ppm) 8.03 (dd, *J* = 8.3, 1.1 Hz, 2H), 7.70 – 7.65 (m, 1H), 7.58 – 7.53 (m, 4H), 7.28 (d, *J* = 8.0 Hz, 2H), 5.18 – 5.10 (m, 1H), 3.86 (dd, *J* = 14.7, 7.6 Hz, 1H), 3.68 (dd, *J* = 17.1, 10.6 Hz, 1H), 3.61 – 3.54 (m, 4H), 3.37 – 3.28 (m, 1H), 2.51 (dt, *J* = 3.5, 1.7 Hz, 1H), 2.35 (s, 3H); ¹³C NMR (101 MHz, DMSO) δ (ppm) 196.7, 157.4, 140.6, 136.4, 134.0, 129.8, 129.2, 128.5, 127.1, 126.6, 75.2, 56.6, 48.0 (dt, *J* = 42.4, 21.1 Hz), 31.4, 21.4; HRMS calcd for C₂₀H₂₁NNaO₄S⁺ (M+Na⁺): 394.1083, found: 394.1089.



3-(naphthalen-2-yl)-5-(((2-(pyridin-2-yl)ethyl)sulfonyl)methyl)-4,5-dihydroisoxazole (**3m**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.53 (d, J = 4.1 Hz, 1H), 7.94 – 7.89 (m, 2H), 7.86 – 7.83 (m, 3H), 7.63 (td, J = 7.7, 1.8 Hz, 1H), 7.56 – 7.50 (m, 2H), 7.25 (d, J = 7.8 Hz, 1H), 7.16 (dd, J = 7.1, 5.3 Hz, 1H), 5.31 (dq, J = 10.5, 6.4 Hz, 1H), 3.77 – 3.68 (m, 3H), 3.53 (dd, J = 14.4, 6.7 Hz, 1H), 3.45 (dd, J = 16.9, 7.0 Hz, 1H), 3.37 (t, J = 7.8 Hz, 2H), 3.19 (dd, J = 14.4, 6.0 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 157.1, 157.0, 149.5,

136.8, 134.2, 132.9, 128.7, 128.4, 127.8, 127.4, 126.8, 126.1, 123.3, 123.3, 122.1, 74.9, 57.3, 53.7, 40.4, 29.9; HRMS calcd for $C_{21}H_{20}N_2NaO_3S^+$ (M+Na⁺): 403.1087, found: 403.1095.



3-Phenyl-6-(((2-(pyridin-2-yl)ethyl)sulfonyl)methyl)-5,6-dihydro-4*H*-1,2-oxazine (**3n**) ¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.54 (d, *J* = 4.1 Hz, 1H), 7.81 (d, *J* = 7.1 Hz, 2H), 7.62 (td, *J* = 7.7, 1.8 Hz, 1H), 7.46 – 7.42 (m, 1H), 7.39 – 7.35 (m, 2H), 7.22 (d, *J* = 7.8 Hz, 1H), 7.17 (dd, *J* = 7.1, 5.3 Hz, 1H), 4.76 – 4.67 (m, 1H), 3.98 – 3.90 (m, 1H), 3.85 – 3.77 (m, 1H), 3.47 – 3.34 (m, 3H), 3.18 – 3.06 (m, 2H), 2.99 – 2.89 (m, 1H), 2.51 – 2.40 (m, 1H), 1.85 – 1.75 (m, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 174.2, 157.7, 149.5, 136.6, 133.7, 130.9, 128.5, 127.9, 123.3, 121.9, 67.4, 58.8, 53.5, 35.1, 30.4, 29.1; HRMS calcd for C₁₈H₂₀N₂NaO₃S⁺ (M+Na⁺): 367.1087, found: 367.1094.



2-(2-(((3-Phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)ethyl)pyridine (5a)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.56 (s, 1H), 7.80 (d, *J* = 7.5 Hz, 2H), 7.64 (d, *J* = 6.9 Hz, 3H), 7.42 – 7.18 (m, 7H), 4.18 (d, *J* = 11.9 Hz, 2H), 3.73 – 3.63 (m, 2H), 3.41 (t, *J* = 9.8 Hz, 4H), 3.29 – 3.22 (m, 1H), 2.37 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) (ppm) 158.3, 156.6, 149.4, 144.8, 136.7, 130.8, 130.4, 123.0, 129.6, 128.8, 128.5, 126.8, 123.3, 122.0, 57.4, 56.0, 53.3, 39.8, 29.9, 21.5; HRMS calcd for C₂₄H₂₅N₃NaO₄S₂⁺ (M+Na⁺): 506.1179, found: 506.1188.



2-(2-(((3-(4-Methoxyphenyl)-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)eth yl)pyridine (**5b**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.57 (d, *J* = 4.1 Hz, 1H), 7.80 (d, *J* = 8.3 Hz, 2H), 7.66 (td, *J* = 7.7, 1.8 Hz, 1H), 7.61 – 7.58 (m, 2H), 7.29 (d, *J* = 8.2 Hz, 3H), 7.20 (dd, *J* = 7.1, 5.2 Hz, 1H), 6.87 (d, *J* = 8.9 Hz, 2H), 4.20 – 4.10 (m, 2H), 3.82 (s, 3H), 3.68 (dd, *J* = 9.0, 6.6 Hz, 2H), 3.43 – 3.33 (m, 4H), 3.21 (dd, *J* = 17.6, 10.2 Hz, 1H), 2.38 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 161.7, 158.1, 156.7, 149.5, 144.8, 136.8, 130.4, 129.7, 128.9, 128.6, 123.4, 122.6, 122.1, 114.0, 57.6, 55.9, 55.3, 53.4, 40.0, 30.0, 21.6; HRMS calcd for C₂₅H₂₇N₃NaO₅S₂⁺ (M+Na⁺): 536.1284, found: 536.1293.



2-(2-(((3-(4-(*tert*-Butyl)phenyl)-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)e thyl)pyridine (**5c**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.58 (d, *J* = 4.4 Hz, 1H), 7.80 (d, *J* = 8.3 Hz, 2H), 7.67 (td, *J* = 7.7, 1.8 Hz, 1H), 7.60 (d, *J* = 8.5 Hz, 2H), 7.40 (d, *J* = 8.5 Hz, 2H), 7.29 (d, *J* = 8.3 Hz, 3H), 7.21 (dd, *J* = 7.2, 5.1 Hz, 1H), 4.20 – 4.11 (m, 2H), 3.70 (d, *J* = 7.3 Hz, 1H), 3.67 (d, *J* = 5.8 Hz, 1H), 3.45 – 3.31 (m, 4H), 3.23 (dd, *J* = 17.7, 10.2 Hz, 1H), 2.39 (s, 3H), 1.32 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 158.3, 156.7, 154.5, 149.6, 144.9, 136.9, 130.5, 129.8, 128.9, 127.3, 126.9, 125.7, 123.4, 122.2, 57.8, 56.0, 53.5, 40.0, 34.9, 31.1, 30.1, 21.6; HRMS calcd for C₂₈H₃₃N₃NaO₄S₂⁺ (M+Na⁺): 540.1985, found: 540.1995.



2-(2-(((1-tosyl-3-(4-(Trifluoromethyl)phenyl)-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulf onyl)ethyl)pyridine (**5d**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.57 (d, *J* = 4.1 Hz, 1H), 7.78 (dd, *J* = 13.5, 8.2 Hz, 4H), 7.70 – 7.61 (m, 3H), 7.30 (dd, *J* = 11.9, 9.0 Hz, 3H), 7.21 (dd, *J* = 7.0, 5.2 Hz, 1H), 4.30 – 4.16 (m, 2H), 3.70 (dd, *J* = 8.8, 6.7 Hz, 2H), 3.50 – 3.36 (m, 4H), 3.28 (dd, *J* =

17.6, 10.3 Hz, 1H), 2.40 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 156.8 (d, *J* = 35.1 Hz), 149.5, 145.2, 136.9, 133.4, 132.4 (q, *J* = 32.8 Hz), 130.5, 129.9, 128.8, 127.2, 125.6 (q, *J* = 3.7 Hz), 123.6 (q, *J* = 271.0 Hz), 123.4, 122.2, 57.5, 56.4, 53.5, 39.7, 30.0, 21.6; HRMS calcd for C₂₅H₂₄F₃N₃NaO₄S₂⁺ (M+Na⁺): 552.1233, found: 552.1248.



2-(2-(((3-(4-Fluorophenyl)-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)ethyl) pyridine (**5e**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.57 (d, *J* = 4.0 Hz, 1H), 7.80 (d, *J* = 8.2 Hz, 2H), 7.69 – 7.63 (m, 3H), 7.32 – 7.27 (m, 3H), 7.22 – 7.18 (m, 1H), 7.06 (t, *J* = 8.6 Hz, 2H), 4.25 – 4.14 (m, 2H), 3.71 – 3.66 (m, 2H), 3.45 – 3.35 (m, 4H), 3.25 (dd, *J* = 17.7, 10.1 Hz, 1H), 2.39 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 164.31 (d, *J* = 252.3 Hz), 157.4, 156.7, 149.6, 145.0, 136.9, 130.5, 129.8, 129.1 (d, *J* = 8.7 Hz), 128.9, 126.45 (d, *J* = 3.4 Hz), 123.5, 122.3, 115.9 (d, *J* = 22.1 Hz), 57.6, 56.2, 53.5, 40.0, 30.1, 21.7; HRMS calcd for C₂₄H₂₄FN₃NaO₄S₂⁺ (M+Na⁺): 524.1084, found: 524.1096.



2-(2-(((3-(4-Chlorophenyl)-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)ethyl) pyridine (**5f**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.57 (d, *J* = 4.4 Hz, 1H), 7.79 (d, *J* = 8.2 Hz, 2H), 7.67 (td, *J* = 7.7, 1.5 Hz, 1H), 7.58 (d, *J* = 8.5 Hz, 2H), 7.35 – 7.27 (m, 5H), 7.20 (dd, *J* = 7.0, 5.3 Hz, 1H), 4.25 – 4.15 (m, 2H), 3.71 – 3.66 (m, 2H), 3.44 – 3.36 (m, 4H), 3.24 (dd, *J* = 17.7, 10.1 Hz, 1H), 2.39 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 157.3, 156.6, 149.5, 145.0, 137.0, 136.9, 130.4, 129.8, 128.9, 128.8, 128.5, 128.2, 123.4, 122.2, 57.5, 56.2, 53.4, 39.8, 30.0, 21.6; HRMS calcd for C₂₄H₂₄ClN₃NaO₄S₂⁺ (M+Na⁺): 540.0789, found: 540.0798.



2-(2-(((3-(3-Chlorophenyl)-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)ethyl) pyridine (**5g**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.57 (d, *J* = 4.6 Hz, 1H), 7.80 (d, *J* = 8.2 Hz, 2H), 7.69 – 7.65 (m, 2H), 7.50 (d, *J* = 7.6 Hz, 1H), 7.39 – 7.36 (m, 1H), 7.33 – 7.28 (m, 4H), 7.21 (dd, *J* = 7.2, 5.1 Hz, 1H), 4.26 – 4.15 (m, 2H), 3.69 (dd, *J* = 8.9, 6.6 Hz, 2H), 3.45 – 3.35 (m, 4H), 3.24 (dd, *J* = 17.7, 10.3 Hz, 1H), 2.40 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 157.1, 156.6, 149.5, 145.1, 136.9, 134.8, 131.8, 130.8, 130.4, 129.9, 129.8, 128.8, 126.8, 125.0, 123.4, 122.2, 57.5, 56.2, 53.5, 39.8, 30.0, 21.6; HRMS calcd for C₂₄H₂₄ClN₃NaO₄S₂⁺ (M+Na⁺): 540.0789, found: 540.0801.



2-(2-(((3-(2-Chlorophenyl)-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)ethyl) pyridine (**5h**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.58 (d, *J* = 4.3 Hz, 1H), 7.83 (d, *J* = 8.2 Hz, 2H), 7.67 (td, *J* = 7.7, 1.7 Hz, 1H), 7.52 (dd, *J* = 7.6, 1.4 Hz, 1H), 7.38 – 7.32 (m, 4H), 7.31 – 7.25 (m, 1H), 7.21 (dd, *J* = 7.1, 5.2 Hz, 1H), 4.25 – 4.15 (m, 2H), 3.68 (dd, *J* = 8.9, 6.7 Hz, 2H), 3.55 (dd, *J* = 18.0, 10.3 Hz, 1H), 3.46 – 3.36 (m, 4H), 2.43 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 158.6, 156.7, 149.6, 145.1, 136.9, 132.9, 131.3, 130.6, 130.5, 129.8, 129.6, 129.1, 126.9, 123.4, 122.2, 57.6, 56.6, 53.5, 42.9, 30.1, 21.7; HRMS calcd for C₂₄H₂₄ClN₃NaO₄S₂⁺ (M+Na⁺): 540.0789, found: 540.0796.



4-(5-(((2-(Pyridin-2-yl)ethyl)sulfonyl)methyl)-1-tosyl-4,5-dihydro-1*H*-pyrazol-3-yl)ben zonitrile (**5i**)

s16

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.58 (d, *J* = 4.1 Hz, 1H), 7.79 (d, *J* = 8.3 Hz, 2H), 7.75 (d, *J* = 8.5 Hz, 2H), 7.70 – 7.65 (m, 3H), 7.34 – 7.27 (m, 3H), 7.22 (dd, *J* = 7.0, 5.2 Hz, 1H), 4.32 – 4.15 (m, 2H), 3.72 – 3.67 (m, 2H), 3.49 – 3.55 (m, 4H), 3.28 (dd, *J* = 17.7, 10.4 Hz, 1H), 2.41 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 156.5, 156.4, 149.6, 145.3, 136.9, 134.2, 132.4, 130.5, 129.9, 128.8, 127.3, 123.4, 122.3, 118.1, 114.1, 57.4, 56.5, 53.5, 39.5, 30.0, 21.6; HRMS calcd for C₂₅H₂₄N₄NaO₄S₂⁺ (M+Na⁺): 531.1131, found: 531.1142.



2-(2-(((3-(Thiophen-2-yl)-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)ethyl)p yridine (**5**j)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.58 (d, *J* = 4.5 Hz, 1H), 7.79 (d, *J* = 8.2 Hz, 2H), 7.67 (td, *J* = 7.7, 1.6 Hz, 1H), 7.43 (d, *J* = 4.8 Hz, 1H), 7.32 – 7.26 (m, 3H), 7.21 (dd, *J* = 7.2, 5.1 Hz, 1H), 7.18 (d, *J* = 3.2 Hz, 1H), 7.02 (dd, *J* = 4.8, 3.9 Hz, 1H), 4.21 – 4.13 (m, 2H), 3.69 (d, *J* = 7.3 Hz, 1H), 3.67 (d, *J* = 6.1 Hz, 1H), 3.44 – 3.33 (m, 4H), 3.27 (dd, *J* = 17.5, 10.3 Hz, 1H), 2.40 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 156.6, 153.9, 149.5, 144.9, 136.9, 133.5, 130.3, 129.8, 129.7, 129.0, 127.6, 123.4, 122.2, 57.5, 56.2, 53.5, 40.6, 30.1, 21.6; HRMS calcd for C₂₂H₂₃N₃NaO₄S₃⁺ (M+Na⁺): 512.0743, found: 512.0753.



2-(2-(((3-(Naphthalen-2-yl)-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)ethyl) pyridine (**5k**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.06 (s, 1H), 7.78 (d, *J* = 8.1 Hz, 2H), 7.60 (d, *J* = 7.1 Hz, 2H), 7.55 (d, *J* = 7.9 Hz, 2H), 7.41 – 7.27 (m, 6H), 7.09 (t, *J* = 7.3 Hz, 1H), 4.25 – 4.13 (m, 2H), 3.61 – 3.51 (m, 3H), 3.40 – 3.26 (m, 2H), 3.01 (t, *J* = 7.4 Hz, 2H), 2.36 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 167.0, 158.8, 145.1, 137.6, 131.0, 130.3,

129.9, 129.9, 129.0, 128.8, 128.7, 127.0, 124.6, 120.0, 57.6, 56.0, 50.3, 39.9, 29.8, 21.6; HRMS calcd for $C_{28}H_{27}N_3NaO_4S_2^+(M+Na^+)$: 556.1335, found: 556.1342.



3-Phenyl-6-(((2-(pyridin-2-yl)ethyl)sulfonyl)methyl)-1-tosyl-1,4,5,6-tetrahydropyridaz ine (**5**I)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.54 (d, *J* = 3.5 Hz, 1H), 7.87 (d, *J* = 8.2 Hz, 2H), 7.70 – 7.67 (m, 2H), 7.63 (t, *J* = 7.6 Hz, 1H), 7.39 – 7.27 (m, 6H), 7.19 – 7.14 (m, 1H), 4.97 (s, 1H), 3.68 – 3.64 (m, 2H), 3.46 (dd, *J* = 14.0, 2.0 Hz, 1H), 3.39 – 3.34 (m, 2H), 3.15 (dd, *J* = 14.0, 10.9 Hz, 1H), 2.72 – 2.43 (m, 3H), 2.41 (s, 3H), 1.77 – 1.67 (m, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 156.8, 149.5, 148.5, 144.4, 136.9, 136.3, 135.0, 129.7, 129.6, 128.4, 128.0, 125.3, 123.5, 122.1, 53.7, 53.5, 46.5, 30.0, 21.6, 21.0, 17.9; HRMS calcd for C₂₅H₂₇N₃NaO₄S₂⁺ (M+Na⁺): 520.1335, found: 520.1346.



5-(*p*-Tolyl)-2-(((4-(trifluoromethyl)benzyl)sulfonyl)methyl)-3,4-dihydro-2*H*-pyrrole (**5m**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.59 (s, 2H), 7.78 (d, *J* = 8.2 Hz, 2H), 7.64 (d, *J* = 6.9 Hz, 2H), 7.44 – 7.34 (m, 3H), 7.30 (d, *J* = 8.1 Hz, 2H), 7.26 (d, *J* = 3.3 Hz, 2H), 4.22 (qd, *J* = 10.3, 2.2 Hz, 1H), 4.09 (dd, *J* = 14.0, 2.3 Hz, 1H), 3.57 (dd, *J* = 14.0, 9.7 Hz, 1H), 3.50 – 3.44 (m, 2H), 3.38 (dd, *J* = 10.5, 4.6 Hz, 2H), 3.27 – 3.20 (m, 2H), 2.39 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 158.7, 150.2, 146.3, 145.1, 131.0, 130.4, 129.9, 129.8, 128.8, 128.7, 127.0, 123.8, 57.2, 56.0, 54.8, 39.7, 27.4, 21.6; HRMS calcd for C₂₄H₂₅N₃NaO₄S₂⁺ (M+Na⁺): 506.1179, found: 506.1185.



1-Phenyl-3-(((3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)propan-1 -one (**5n**) ¹H NMR (400 MHz, DMSO) δ (ppm) 8.05 (d, *J* = 7.5 Hz, 2H), 7.75 (d, *J* = 8.1 Hz, 2H), 7.70 – 7.65 (m, 3H), 7.57 (t, *J* = 7.6 Hz, 2H), 7.49 – 7.42 (m, 5H), 4.22 (q, *J* = 9.2 Hz, 1H), 4.05 – 3.92 (m, 1H), 3.69 – 3.58 (m, 4H), 3.51 (dd, *J* = 17.6, 11.0 Hz, 1H), 3.39 – 3.30 (m, 1H), 2.36 (s, 3H); ¹³C NMR (101 MHz, DMSO) δ (ppm) 196.5, 159.9, 145.3, 136.4, 134.1, 131.4, 131.2, 130.6, 130.4, 129.3, 129.3, 128.9, 128.6, 127.4, 57.2, 56.5, 49.0, 39.9, 31.6, 21.6; HRMS calcd for C₂₆H₂₆N₂NaO₅S₂⁺ (M+Na⁺): 533.1175, found: 533.1186.



Phenyl 3-(((3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)propanoate (**50**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.80 (d, *J* = 8.2 Hz, 2H), 7.65 (d, *J* = 6.9 Hz, 2H), 7.44 – 7.35 (m, 5H), 7.30 – 7.25 (m, 3H), 7.14 (d, *J* = 7.7 Hz, 2H), 4.26 – 4.16 (m, 2H), 3.64 – 3.50 (m, 3H), 3.42 (dd, *J* = 17.6, 10.5 Hz, 1H), 3.34 – 3.26 (m, 1H), 3.21 (t, *J* = 7.3 Hz, 2H), 2.38 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 168.8, 158.4, 150.3, 145.0, 131.0, 130.5, 130.0, 129.8, 129.5, 128.9, 128.7, 127.0, 126.2, 121.3, 57.86, 56.0, 49.9, 39.9, 27.2, 21.6; HRMS calcd for C₂₆H₂₆N₂NaO₆S₂⁺ (M+Na⁺): 549.1124, found: 549.1132.



Benzyl 3-(((3-phenyl-1-tosyl-4,5-dihydro-1H-pyrazol-5-yl)methyl)sulfonyl)propanoate (5p)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.79 (d, *J* = 8.3 Hz, 2H), 7.64 (d, *J* = 6.7 Hz, 2H), 7.43 – 7.32 (m, 8H), 7.28 (d, *J* = 8.1 Hz, 2H), 5.19 (s, 2H), 4.21 – 4.12 (m, 2H), 3.52 – 3.35 (m, 4H), 3.23 (dd, *J* = 17.7, 10.0 Hz, 1H), 2.99 (t, *J* = 7.4 Hz, 2H), 2.38 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 169.9, 158.4, 144.9, 135.1, 130.9, 130.5, 130.0, 129.8, 128.84, 128.6, 128.6, 128.5, 128.4, 127.0, 67.3, 57.8, 56.0, 49.9, 39.9, 27.1, 21.6; HRMS calcd for C₂₇H₂₈N₂NaO₆S₂⁺ (M+Na⁺): 563.1281, found: 563.1287.



N-Phenyl-3-(((3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)propana mide (**5q**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 8.58 (d, *J* = 4.1 Hz, 1H), 7.96 (dd, *J* = 8.7, 1.5 Hz, 1H), 7.88 – 7.78 (m, 6H), 7.67 (td, *J* = 7.7, 1.7 Hz, 1H), 7.54 – 7.46 (m, 2H), 7.29 (d, *J* = 8.1 Hz, 3H), 7.21 (dd, *J* = 7.0, 5.2 Hz, 1H), 4.28 – 4.19 (m, 2H), 3.72 (d, *J* = 7.2 Hz, 1H), 3.70 (d, *J* = 6.0 Hz, 1H), 3.56 (dd, *J* = 17.5, 10.7 Hz, 1H), 3.45 – 3.33 (m, 4H), 2.36 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 158.4, 156.7, 149.5, 144.9, 136.9, 134.3, 132.7, 130.5, 129.8, 128.9, 128.5, 128.5, 127.9, 127.7, 127.6, 127.6, 126.8, 123.4, 123.3, 122.2, 57.7, 56.2, 53.5, 39.9, 30.1, 21.6; HRMS calcd for C₂₆H₂₇N₃NaO₅S₂⁺ (M+Na⁺): 548.1284, found: 548.1296.



N,N-Dimethyl-3-(((3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)prop anamide (**5r**)

¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.81 (d, *J* = 8.1 Hz, 2H), 7.66 (d, *J* = 6.9 Hz, 2H), 7.44 – 7.36 (m, 3H), 7.31 (d, *J* = 8.0 Hz, 2H), 4.24 – 4.15 (m, 2H), 3.54 (t, *J* = 7.4 Hz, 2H), 3.49 – 3.39 (m, 2H), 3.26 (dd, *J* = 17.7, 10.1 Hz, 1H), 3.08 (s, 3H), 3.01 (s, 3H), 2.94 (t, *J* = 7.4 Hz, 2H), 2.39 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 168.5, 158.3, 144.9, 130.9, 130.6, 130.1, 129.8, 128.9, 128.7, 127.0, 58.0, 56.1, 50.4, 40.0, 37.1, 35.8, 26.0, 21.6; HRMS calcd for C₂₂H₂₇N₃NaO₅S₂⁺ (M+Na⁺): 500.1284, found: 500.1299.



(8*S*,9*S*,13*S*,14*S*)-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6*H*-cyclopenta[*a*]phen anthren-3-yl

3-(((3-phenyl-1-tosyl-4,5-dihydro-1*H*-pyrazol-5-yl)methyl)sulfonyl)propanoate (**5s**) ¹H NMR (400 MHz, CDCl₃) δ (ppm) 7.81 (d, *J* = 8.3 Hz, 2H), 7.66 (dd, *J* = 8.1, 1.4 Hz, 2H), 7.44 – 7.35 (m, 3H), 7.30 (d, *J* = 8.3 Hz, 3H), 6.92 – 6.87 (m, 2H), 4.26 – 4.16 (m, 2H), 3.62 – 3.39 (m, 4H), 3.29 (dd, *J* = 17.7, 9.9 Hz, 1H), 3.19 (t, *J* = 7.3 Hz, 2H), 2.92 (dd, *J* = 8.5, 3.8 Hz, 2H), 2.55 – 2.40 (m, 2H), 2.39 (s, 3H), 2.32 – 2.25 (m, 1H), 2.19 – 1.94 (m, 4H), 1.63 – 1.42 (m, 6H), 0.88 – 0.83 (m, 1H); ¹³C NMR (101 MHz, CDCl₃) δ (ppm) 169.1, 158.4, 148.2, 145.0, 138.2, 137.8, 131.0, 130.5, 130.0, 129.8, 128.9, 128.7, 127.0, 126.5, 121.3, 118.5, 57.9, 56.0, 50.4, 50.0, 47.9, 44.1, 39.9, 37.9, 35.8, 31.5, 29.3, 27.3, 26.3, 25.7, 21.5, 13.8; HRMS calcd for C₃₇H₄₀N₂NaO₇S₂⁺ (M+Na⁺): 711.2169, found: 711.2175.













































































































s76





















